FindTrial
Sign In

The use of plasma B-type natriuretic peptide (BNP) in the prognosis of patent ductus arteriosus in preterm baby.

ROLE OF B-TYPE NATRIURETRIC PEPTIDE (BNP) FOR THE PROGNOSIS OF PATENT DUCTUS ARTERIOUSUS IN PRETERM INFANT - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/09/074470
Enrollment
24
Registered
2024-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: Q250- Patent ductus arteriosus

Interventions

Intervention1: 2D echocardiography and plasma BNP level: 2D echocardiography and plasma BNP level after 24 hr of life Intervention2: 2D ECHO AND PLASMA BNP LEVEL: 2D ECHO AND PLASMA BNP LEVEL AFTER 24

Sponsors

INTRAMURAL GRANT PROGRAM-FACULTY-2023
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: PRETRM NEONATES AND LESS THAN 28 DAYS

Exclusion criteria

Exclusion criteria: TERM NEONATES

Design outcomes

Primary

MeasureTime frame
NICU stay, size of PDA, Requirement of medical or surgical interventionTimepoint: BEFORE DISCHARGE OR 4 WEEKS—

Secondary

MeasureTime frame
NICU STAY AND MORTALITYTimepoint: 30 DAYS—

Countries

India

Contacts

Public ContactDINESH HINGE

JNMC,SAWANGI(M) WARDHA

dineshhingemgims@gmail.com9665838726

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026